Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Https://prevention.cancer.gov/news-and-events/blog/improved-prostate-cancer-biomarker-test-may-help-men-avoid-unnecessary-biopsy
Note the earlier version of this test is already in the NCCN guidance so this improved version will most likely be included too. Gaining access to these guidance notes for PSE is what Arrivo is tasked with.
Something must be happening, these two negative derampers are at it first thing, I'd say for a cheaper price, but could it get any lower 🤣
Dusty.
You can whine about deramping if you.like but I suggest you open your eyes, read the article (published just a couple of weeks ago) and start recognising that PSE is no longer unique, world leading and at the forefront. It may just save you some money.
Dusty
You are a fool
Don’t want to see any negative in the share
Dug if you no longer believe in this investment, then why are you here? If this had zero opportunity that you consistently allude to I'd have just cut my losses and see no need to post, but your here hanging on whining, posting everything bad about it, but holding on.
Your such a bizzare fellow
None so blind as those that will not see.
I don't mind negative, and believe me there is plenty of Kong, but it's pointless coming on for a whinge and moan all the time. Get some sense man, or just sell instead if boring us by consistent stating of the obvious
I see dug, but I speak for many in I'm sick of hearing
I have cut my losses here as I posted in here many months ago. I retain a token holding out of sentiment as I was once a strong advocate of the science/technology. I continue to post to warn others of the risks of investing in what increasingly feels like a lifestyle company and to bring relevant facts for the consideration of those still invested more heavily than me.
So have you read the article? Do you think.it represents a risk to OBD's commercial ambitions or not?
You should be grateful that others are willing to share their research with you as you apparently don't do much of your own.
I'm not here to provide my research or read yours, I think you mistake my silence on matters of information as blind to it, I'm fully aware of my investment, I'd say considerably more than you, from your posts. And having sold, you wanted your money sooner and unfortunately it didn't happen. I'm a little more patient and not in any rush, today's prices may not be 2025 prices, you just won't be here to find out.
And if fresh investors arrive, I'll give them a more balanced view of the risk, not your doom and gloom version.
Each day its a hack version, even tho you left a token investment because you hang on to that shred of belief. But our soured by the loss
So let's keep the discussion focused on relevant facts. Do you think the urine test I have referenced is a threat to OBD's ambitions or not? If so why? If not why? Then we can have a sensible debate without your constant whining about deramping.
Well considering its really early stage and only in the results stage, and urine related markers being historically spotty at best.
Having read about it 3 weeks back I didn't see it as a direct threat, or consider it as something I would consider investing material above this.
I think they will struggle
You say it is early stage.
Do you know how many tests were done using the earlier version of the test?
Are you aware that the cohort used for initial validation is 7 times the size of the OBD cohort tested under Prostogram? He sensitivity data from this larger US cohort is very impresdive.
Admittedly both tests suffer the same limitations wrt genetic mix and age range of those tested and in that regard both are 'early stage' and desperately need further validation. The urine test was developed with fundi g from the US National Cancer institute and is ahead of PSE in that the previous less affective version is already in the NCCN guidelines, something OBD are still working towards. So you will need to explain why you claim it is early stage but OBD is not. Why will they struggle more than OBD to gain traction? A test funded by the NCI producing results comparable to PSE from a larger cohort and based on a completely non-invasive test would seem.to me to be in a better position to gain acceptance in the US market than PSE.
I don't, I gave my opinion, I'm.not here for lengthy debates on this investment I've been there done that. I'm just sitting tight, I have other things to tend to, than play to your tune
You need to 🤣🤣
I really dont
So your not here to share research, nor are you here to debate the pros and cons of the investment. You are bored reading the contributions yet here you are? You are either a fool or desperately trying to ramp the share price. Your accusation that I am deramping suggests the former.
Burrows appears to be running a friends and relatives club. He is prone to exaggeration, and misleading gullible shareholders with promises of exponential sales growth or 3rd parties lining up.to buy a slice of the corporate IP so that placements would not be needed. As things stand I wouldn't touch these shares at half the price. It seems too that the CSO and Vulpes have recently decided discretion is the better part of valour.
Dug
Why would people trust your "research" are you an expert in the area?
I agree with the general sentiment that things could be better but I personally wouldn't rely on your posts especially as you seemed to be the only one who couldn't understand the annual results announcement see the many posts from you on the morning of the 17th January when you were again clogging up the board as you misunderstood the results and others were telling you, you were wrong but you stuck to your misunderstanding!
DugWalker
Posted in:Â OBD
Posts:Â 484
Price:Â 34.00
No Opinion
RE: What matters.17 Jan 2024 07:15
So in the 3.5 months since end of the financial year we have sold 770 CiRT tests which is more than in 2022 & 2023 combined. It equates to an average of 220 per month equivalent to a monthly growth rate of 20% since we were told we had reached 90 a month back in July.
If that growth rate is maintained (more likely it will be surpassed) we get above 400 tests a month by end April this year.
If the reimbursement rate is still £2000 per month we will bring in enough.money to become profit making this year.
Fantastic news!
DugWalker
Posted in:Â OBD
Posts:Â 484
Price:Â 28.40
No Opinion
RE: Disapointed17 Jan 2024 08:37
@GMS. Sales have NOT been stagnant. They have sold 770 CiRT tests since the end of last financial year (Oct 31). On a monthly basis sales have grown by at least 20% per month since July last year and are probably sitting somewhere around 300 a month right now!
DugWalker
Posted in:Â OBD
Posts:Â 484
Price:Â 25.60
No Opinion
RE: Disapointed17 Jan 2024 08:57
The 770 sales figure is given in the section entitled Post Year End Highlights. There is no doubt in my mind that it is the total since October 1st last. Might be a more than a few regretting selling come 4:00 p.m. today
Looks like dugs is going to be here all day trying to save people money,what a guy.
No dug, it's my day off and as people have mentioned, your talking out your backside on occasions.
So it's not necessary for me to take time out my schedule to debate.
I have mentioned recently, I will find my exit plan and take it.
What I won't do is ramp or deramp or sit around complaining . I'll leave that to you
I dont think its worth wasting your time .. Dug has interpreted almost everything wrong, takes him about 4 hours to read RNS from ulimate uniformed ramper and now "Placing due", it doesnt work etc.. TBH I feel sorry for him - Clearly sat there dreaming of millions - you can tell by the way you frantically post and only ever see one side that you overleveraged and blown your all money. retain a small holding (as if -chuckle) and now hang around venting your own inadequacies on the BB's..its sad. I not happy with OBD performance, and it didnt meet my expectations either, but the only one who has mislead investors is DUG .. how can you post "Placing , placing, funds etc " 8 weeks after they raised 10 million? and claim to want to debate facts , I do wonder where these people come from
The company may have just done some good deals
But the sales figures are still not good !
Otherwise they would have included them in the last RNS !
POWERHOUSE ENERGY, is a total stinker. 6 months solid zero news and a total plummet to .25p over that period.
But in the background moves was made, and they hit 2p this week.
Probably go further with what's in pipeline I'm coming weeks.
One great RNS out of knowhere, with a lot of background work. This goes north in no time.
Patience
Spit test is in the Transform Trial ?
Looks like it is. All over the news today. Has obd wasted years and money delivering a gold standard betamax type product which will be overtaken by a cheap and simple at home spit test.
Hardly a breakthough, not sure why that made a front page - marginally better than PSA, and vastly inferior to PSE nothing about transform, and miles behind - but TBH who care about a trial that will take 3 years + from now to draw any conclusion ? Im sure as shareholders you would like to see OBD focus its efforts and finances on that, Instead of having PSE abopted by one of the world leading Prostate Cancer Clinics ? Think of all that real world evidence being generated and followed through .. and it wont take 3 years to build a case for NICE etc. Some sore losers on these BB's.. OBD has some issues to address, but to go from a "unicorn" to betamax in 3 month is moronic